Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

Clinical trial NCT05170256 · UNKNOWN

Trial details

NCT number: NCT05170256
Sponsor: Morten Mau-Sørensen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma HER-2 Protein Overexpression HER-2 Gene Amplification

Start date: 2022-02-04
Primary completion: 2025-01-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.